Senate Democrats on Tuesday pressed President Donald Trump’s nominee for the top health post to explain how he would fight skyrocketing drug prices. Alex Azar is the former president of the U.S. division of Eli Lilly and Trump’s pick to run the Department of Health and Human Services,
In his second successive appearance at the annual StartUp Health Festival in San Francisco, Tuesday, Biden expresses anger, frustration, grief but also hope about the healthcare system.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The text messaging kerfuffle at CMS reflects the changes in the Joint Commission's text messaging policy in the past few years.
A day after President Donald Trump said the Affordable Care Act “has been repealed,” officials reported that 8.8 million Americans have signed up for coverage on the federal insurance exchange in 2018.
CHIP has had a dramatic effect in lower income states like Alabama, where the childhood uninsured rate dropped from 20 percent in 1997 to under 3 percent in 2015.
DeSalvo joins Dell Medical School as the city of Austin seeks to fulfill its ambition to assemble a healthcare innovation zone.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Is all publicity good publicity? Alabama biotech may soon find out. The local industry struggled to gain visibility and interest from investors on either coast — until the rise and fall of Roy Moore put it on the map.
Pharmaceutical Research and Manufacturers of America’s state and federal lobbying spending rose by more than two-thirds from the previous year, to $57 million.
A big part of why people don’t like the health law is that they don’t understand what it does or how it works. Some of that is because healthcare is complicated.
At a hearing held by the Senate Health, Education, Labor and Pensions Committee, experts made nine proposals to lower drug prices. Here's an analysis on the likelihood of action being taken on each of them.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Many of plans that people relied on for 2017 are being canceled, the result of insurers exiting the marketplaces or redesigning coverage to try to keep premiums down.
As different strategies to address the drug-pricing crisis are discussed and considered, it is worth remembering that HHS already has the power necessary to reduce the costs for many patented, life-saving medicines through a provision of the Bayh-Dole Act of 1980.
For the sake of our aging population and all patients, it’s time for reimbursement to evolve. Adequate payment is vital to advancing remote patient monitoring into the mainstream of America’s healthcare ecosystem.
Under the Affordable Care Act, 10 states received grants totaling $85 million to test the use of financial rewards as a way to reduce the risk of chronic disease among their Medicaid populations.
It turns out the tax bills in the House and Senate also aim to reshape healthcare. Here are five ways these bills are trying to achieve that.